ARGX logo

ARGX argenx SE

NASDAQ Global Select · Biotechnology · Healthcare

$941.25
-6.27 (-0.66%)

argenx SE is a biotechnology enterprise dedicated to developing a diverse array of therapeutic agents for autoimmune conditions. Its operational reach extends across the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, and France. The company's primary drug candidate, efgartigimod, is currently in advanced stages of clinical investigation. It is being evaluated in Phase III tr…

Market Cap: $59.19Bwww.argenx.com

Price

No data yet.

Social Signal Score

47
5d
—
30d
43
3 mentions
—
60d
50
19 mentions
—
90d
49
24 mentions
—
news: 24

Analyst Ratings

36 analysts
Buyconsensus
Strong Buy 1Buy 31Hold 4Sell 0Strong Sell 0
Avg price target$1,152+22.4%
Low $861Median $1,150High $1,400
Current Consensus

Revenue

$1.72B+104057.84%
$1.65M$1.07B$2.14B$3.21B
Jun 2014Sep 2026

Analyst Estimates

FY2025
$17.65
$15.78–$20.62
13 analysts
FY2026
$27.46+56% YoY
$26.16–$30.94
9 analysts
FY2027
$37.34+36% YoY
$31.64–$43.72
9 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Karen Massey
Sector
Healthcare
Industry
Biotechnology
Employees
1,863
Beta
-0.02
Country
NL
Piotroski score
4 / 9 (Middling)
Altman Z-score
21.94
www.argenx.com